What is Noveris Health Sciences Inc.'s (NVRS.CN) StockRank?

MoatMap's StockRank for Noveris Health Sciences Inc. (NVRS.CN) is 23/100, with a Sell signal. This is a composite score combining Quality (25), Value (25), and Momentum (60) factor ranks across MoatMap's 20,000+ stock universe.

Does Noveris Health Sciences Inc. have an economic moat?

Noveris Health Sciences Inc. (NVRS.CN) has a Quality factor score of 25/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Noveris Health Sciences Inc. a buy, hold, or sell?

MoatMap's current signal for Noveris Health Sciences Inc. (NVRS.CN) is Sell, based on a StockRank of 23/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Noveris Health Sciences Inc. in?

Noveris Health Sciences Inc. (NVRS.CN) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (Canada).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

NVRS.CN

SELLREMOVE

Noveris Health Sciences Inc. · Healthcare · Canada · $64M · Avg Vol: $196K/d

StockRank

P/E (TTM)

0.8x

ROE

—

D/E

—

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Noveris Health Sciences is a microcap healthcare company that is highly speculative, pre-revenue, and lacks the established moat or cash flows required for our concentrated book.

COMPANY DESCRIPTION

Noveris Health Sciences Inc. is a specialty healthcare company focused on the development and commercialization of generic and specialty pharmaceuticals. The company targets niche therapeutic areas with high barriers to entry, utilizing outsourced manufacturing to maintain a capital-light business model. Noveris positions itself as an agile competitor in the specialty drug market, focusing on cost-effective formulations and regulatory efficiency.

FINANCIAL SUMMARY (USD)

Year	2021	2022	2023	2024	2025	CAGR
Revenue	—	0	0	0	0	—
EPS	—	-9.61	-0.48	-1.88	0.04	—
Shares	—	58.5M	52.6M	61.8M	58.5M	0.0%
Debt	3.1M	3.4M	3.8M	4.9M	6.8M	21.8%
Equity	—	-0.9M	-8.4M	-10.8M	-8.8M	—
Op CF	—	-5.9M	-3.0M	-26,339	6,616	—
Inv CF	-0.3M	-26,495	0.4M	0	—	—
Fin CF	16.8M	4.9M	2.6M	0	—	—

PRICE (1Y)-5.4%

SMA 50SMA 200

$1.23

RSI (14)

31.2

52W High

$2.12

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC (ROA)

-27.5%*24.4

ROE

—N/A

GP/Assets

—N/A

Op. Margin

0.0%40.6

FCF/Assets

-47152.9%0.1

Piotroski

457.0

Int. Cover

14.4x64.8

D/E Ratio

—N/A

Current Ratio

0.47x2.0

Value

P/E (TTM)

0.8x25.0

EV/EBITDA

—N/A

P/FCF

—N/A

P/B

-52.6x25.0

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

58%34.8

RS 6M

453%99.9

SMA 50/200

2.13x99.8

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$64M

P/E (Forward)

—

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NVRS.CN are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
NVRS.CN	Noveris Health Sciences Inc.(you)	$64M	23	SELL
CRDL.TO	Cardiol Therapeutics Inc.	$123M	22	SELL
LEEF.CN	Leef Brands Inc.	$46M	29	SELL
OGI	Organigram Global Inc.	$138M	31	SELL
ACB.TO	Aurora Cannabis Inc.	$180M	30	SELL
OPTI.CN	Optimi Health Corp.	$25M	2	STRONG SELL
DB.V	Decibel Cannabis Company Inc.	$50M	60	HOLD
WEED.TO	Canopy Growth Corporation	$501M	21	SELL
HLS.TO	HLS Therapeutics Inc.	$100M	63	HOLD
TLRY.TO	Tilray Brands, Inc.	$781M	29	SELL

Peer medians: ROE -44.7% · P/E 14.8x · Gross margin 35.6%

Noveris Health Sciences Inc. (NVRS.CN) — Stock Score Summary

Noveris Health Sciences Inc. (NVRS.CN) has a MoatMap StockRank of 23/100 based on Quality (25/100), Value (25/100), and Momentum (60/100) factor scores. The current signal is SELL. Noveris Health Sciences is a microcap healthcare company that is highly speculative, pre-revenue, and lacks the established moat or cash flows required for our concentrated book.

Key Financial Metrics

Price	$1.23
Market Cap	$64M
P/E (TTM)	0.80
Price/Book	-52.63
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-3M

Noveris Health Sciences Inc. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (Canada).

Frequently Asked Questions

What is Noveris Health Sciences Inc.’s (NVRS.CN) StockRank?: MoatMap’s StockRank for Noveris Health Sciences Inc. (NVRS.CN) is 23/100, with a Sell signal. It is a composite of Quality (25), Value (25), and Momentum (60) factor ranks across MoatMap’s 20,000+ stock universe.
Does Noveris Health Sciences Inc. have an economic moat?: Noveris Health Sciences Inc. (NVRS.CN) has a Quality factor score of 25/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Noveris Health Sciences Inc. a buy, hold, or sell?: MoatMap’s current signal for Noveris Health Sciences Inc. (NVRS.CN) is Sell, based on a StockRank of 23/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Noveris Health Sciences Inc. in?: Noveris Health Sciences Inc. (NVRS.CN) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (Canada).